Neuberger Berman Group’s Viking Therapeutics VKTX Stock Holding History

Neuberger Berman Group’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$236K	Buy	+6,038	New	+$195K	﹤0.01%	2111
2025 Q2	–	Sell	-10,393	Closed	-$251K	–	2123
2025 Q1	$251K	Buy	+10,393	New	+$328K	﹤0.01%	1752
2024 Q3	–	Sell	-70,669	Closed	-$3.75M	–	1996
2024 Q2	$3.75M	Buy	70,669 +4,136	+6%	+$271K	﹤0.01%	971
2024 Q1	$5.46M	Sell	66,533 -146,465	-69%	-$6.52M	﹤0.01%	901
2023 Q4	$3.96M	Buy	212,998 +128,687	+153%	+$1.68M	﹤0.01%	1110
2023 Q3	$933K	Buy	84,311 +1,490	+2%	+$21.3K	﹤0.01%	1276
2023 Q2	$1.34M	Buy	+82,821	New	+$1.74M	﹤0.01%	1174

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Neuberger Berman Group's VKTX Position: Q2 2026 in Review

Neuberger Berman Group opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 6,038 shares worth $236K. The stake represents ﹤0.01% of the portfolio and ranks #2111 among its holdings. This is a return to the name: Neuberger Berman Group previously reported a position in VKTX as recently as Q1 2025.

Neuberger Berman Group first reported a position in VKTX in Q2 2023 and has held it in 7 quarters since. The position peaked at $5.46M in Q1 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Neuberger Berman Group held 6,038 shares of Viking Therapeutics worth $236K as of Q2 2026.
Viking Therapeutics was a new Neuberger Berman Group position in Q2 2026.
Viking Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2111 holding.
Neuberger Berman Group first reported a position in Viking Therapeutics in Q2 2023 and has held it in 7 quarters since.
Neuberger Berman Group's Viking Therapeutics position peaked at $5.46M in Q1 2024.
436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.